BIT's 6th Annual World Congress of NeuroTalk-2015
★ Submission Guideline

1. The organizers of NeuroTalk-2015 welcome all abstracts within the scope of the meeting. Submitted abstracts will be reviewed by experts and be scheduled for oral or poster presentation during the congress if the topic is relevant and the quality of the data justifies its scheduling. Irrelevant or poor-quality abstracts may be rejected.

 

2. Abstracts may only be submitted by email to rose@bit-neurotalk.com . It is advisable to prepare the complete text of your abstract as well as any figures or tables before abstract submission.

 

3. Abstracts need to written in clear English, taking into account the specifications belows:

  1. Maximum word count abstract title: 20 words.
  2. Maximum word count abstract text: 350 words (adjust in case of tables./figures).
  3. Abstract topic should be selected during the online submission process from the list of predefined topics to facilitate abstract review and scheduling.
  4. A minimum of three specific keywords should be added during online submission for indexing of the abstract. Specific keywords are: name(s) of drug(s) investigated, molecular target molecule(s), disease(s) studied, biochemical or biological function(s) studied. Avoid the use of non-specific keywords, such as: angiogenesis, cell death, cancer, tumor, drug development, drug therapy. The Organizing Committee of NeuroTalk-2015 reserves the rights to delete, edit, or add keywords to achieve uniformity throughout abstract publications.
  5. Use International Nonproprietary Names (INN) or research codes to identify drugs throughout the abstract. Proprietary names may be used in the abstract text, not the abstract title; the first time the drug is mentioned there (put proprietary names between brackets).
  6. The identity of a new, previously unpublished drug substance needs to be disclosed in the abstract, either by providing its structural formula or its full chemical name.

4. Abstracts will be published exactly as submitted. No editing of abstract texts will be done. However, non-adherence to the above guidelines may be corrected (e.g. use of drug names, keywords) by the meeting organizers.

 

5. After submission abstracts can no longer be changed by the authors. Should minor changes be necessary after submission, the author should notify Ms. Rose Yan by email at rose@bit-neurotalk.com , describing exactly the nature of the change to be made. The NeuroTalk-2014 organizers will then implement the change. If major changes are required the author should submit a revised abstract as an entirely new abstract and send a request to rose@bit-neurotalk.com to delete the original abstract. The addition of a co-author constitutes a major change.

 

6. After completion of the abstract review, the submitting author will receive scheduling information via email. Abstracts cannot be withdrawn after receipt of the scheduling information by the submitting author. The presenting author must be registered as a NeuroTalk-2015 participant for final scheduling and publication of the abstract.

 

7. Accepted abstracts will be published in the Congress Proceedings. The authors of the submitted abstracts will take responsibilities of any Intellectual Property issues about the abstracts on their own. The organizing committee of NeuroTalk-2015 has the legal rights to use the submitted abstracts for conference purpose.

Concurrent Congress
News Released

• Updated Program released
REGISTER NOW to secure your attendance

Hosting Organization

Information Research Center of International Talents, SAFEA

Co-organizations
Zhejiang Administration of Foreign Experts Affairs
Zhejiang Association for International Exchange of Personnel (ZAIEP)
Operating Organizations

BIT Congress Inc.

Foreign Experts Databank of SAFEA-Dalian Branch

Supporting Organization
Hangzhou Municipal Tourism Committee
Official Travel Agency

BIT World Travel Service, Inc.

Renowned Speakers-2015
Dr. Vladimir J. Konecni,
Professor, University of California, San Diego, USA
Dr. James P. Chandler,
Co-director and Surgical Director, Northwestern Brain Tumor Institute, USA
Dr. Richard H. Mattson,
Professor, Yale University School of Medicine,USA
Dr. Andrey Y. Abramov,
Professor, UCL Institute of Neurology, UK
Dr. Jaime Tisnado,
Professor, MCV Hospitals/VCU Medical Center, USA
Dr. Urs Ribary,
Professor and Endowed BC LEEF Leadership Chair, Simon Fraser University, Canada
Dr. Ying Xia,
Professor and Vice-Chairman for Research, The University of Texas Medical School at Houston, USA
Dr. Jerzy Trojan,
Professor, INSERM, France, and NIH (INS), Colombia
Dr. Magnus S. Magnusson,
Research Professor, University of Iceland, Iceland
Dr. Raimund Firsching,
Professor, Universitaetsklinik fuer Neurochirurgie, Germany
Dr. Laura Gaudet,
Professor & Chair, Chadron State College, USA
Dr. Gerhard Technau,
Professor, Mainz University, Germany
Dr. Walter E. Muller,
Director, University of Frankfurt, Germany
Dr. Anna Petroni,
Professor, University of Milan, Italy
Dr. Chris Baeken,
Professor, University of Ghent (UGent), University of Brussels (VUB), Belgium
Dr. Hugh Brent Solvason,
Associate Professor, Stanford University, USA
Dr. Kwan-Pin Su,
Professor & Chairman, Graduate Institute of Neural and Cognitive Sciences, China Medical University, Taiwan
Dr. Steven K Juhn,
Professor, University of Minnesota, USA
Dr. Alfredo Gorio,
Professor and President of The Cognitive Neuroscience Program, University of Milan, Italy
Dr. Ubaldo Armato,
Professor, Senior Investigator, The University of Verona Medical School, Italy
Dr. Flemming F Johansen,
Professor, University of Copenhagen, Denmark
Dr. Sylvain Doré,
Professor and Director, University of Florida College of Medicine, USA
Dr. Cheil Moon,
Department Chair, Department of Brain Science, DGIST, Korea
Dr. Xuejun H. Parsons,
Co-Founder & President, San Diego Regenerative Medicine Institute, USA
Dr. Ilan Ziv,
Professor, Tel Aviv University, Iseal
Dr. Andrew Todd-Pokropek,
Professor, University College London, UK
Dr. Nicole von Steinbüchel,
Professor, Georg-August-University, Germany
Dr. Fayz Al Shahry,
Chief, Rehabilitation Services, Ministry of National Guard – Health Affairs, Kingdom of Saudi Arabia
Dr. John K-J. Li, 
Distinguished Professor, Rutgers University, USA
Contact Us

Add: East Area, F11, Building 1, Dalian Ascendas IT Park, 1 Hui Xian Yuan, Dalian Hi-tech Industrial Zone, LN 116025, China]
Tel: 0086-411-84799609, Fax: 0086-411-84796897
Copyright © 2014-2015 BIT Congress Inc.